Cellular Biomedicine Group to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference
24 nov. 2015 09h07 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Announces Voting Results of 2015 Annual General Meeting
23 nov. 2015 09h10 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Reports Third Quarter 2015 Financial Results and Provides Business Highlights
13 nov. 2015 09h20 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group to Present HER-1-Targeted CAR-T Immunotherapy at CAR-T Summit 2015
11 nov. 2015 09h18 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Opens New GMP Facility in Beijing
09 nov. 2015 09h00 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
CBMG Responds to Inquiries From Investors and the Scientific Community About the Phase IIa Results From CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced B-cell Non-Hodgkin Lymphoma
03 nov. 2015 09h20 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Presented Phase IIa Results From CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced B-cell Non-Hodgkin Lymphoma
28 oct. 2015 16h01 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group to Present Phase IIa Results from CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced Diffuse Large B Cell Lymphoma
23 oct. 2015 08h15 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Calls for General Annual Stockholder Meeting on November 20, 2015
20 oct. 2015 09h00 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Announces Positive Results From CAR-T EGFR Immunotherapy in Advanced Relapsed/Refractory Patients With Solid Tumors
28 sept. 2015 08h56 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and PALO ALTO, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of...